Plasma Amiloid β42 in Patients with Obstructive Sleep Apnea before and after CPAP-Therapy: Pilot Study
The aim of this pilot research was to assess the sleep fragmentation influence on amyloid β42 (Aβ42) plasma levels before and after СPAP in patients with obstructive sleep apnea (OSA). Materials and Methods: The study involved 24 patients (mean age of 52.5±2.7 years) with OSA and 20 persons withou...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Medical Research and Development Corporation
2019-09-01
|
| Series: | International Journal of Biomedicine |
| Subjects: | |
| Online Access: | http://ijbm.org/articles/i35/ijbm_9(3)_oa3.pdf |
| Summary: | The aim of this pilot research was to assess the sleep fragmentation influence on amyloid β42 (Aβ42) plasma levels before and after СPAP in patients with obstructive sleep apnea (OSA).
Materials and Methods: The study involved 24 patients (mean age of 52.5±2.7 years) with OSA and 20 persons without OSA (mean age of 49.1±8.2 years). All participants underwent overnight polysomnography. The Aβ42 level was determined in blood plasma by an immunoassay method. Patients with OSA were treated with auto-CPAP for 3 months.
Results: The research showed the following results in patients with OSA before CPAP, as compared to control: sleep fragmentation 1–2 times, increases in non-rapid eye movement sleep stage by 60% (P<0.05) and arousal index by 55% (P<0.05), and decreases in slow-wave sleep duration by 40% (P<0.05) and rapid-eye-movement sleep by 43% (P<0.05). After CPAP-therapy, a decrease in arousal index by 40% (P<0.05) and apnea/hypopnea index (P<0.05), and increases in oxygen saturation by 17% (P<0.05), the slow-wave sleep duration by 56% (P<0.05) and rapid-eye-movement sleep by 55% (P<0.05) were found. Aβ42 levels were significantly lower in the group with OSA before CPAP-therapy, as compared to the control group and the group with OSA after CPAP-therapy (P<0.05). There were no differences in Aβ42 levels after treatment between control and main group.
Conclusion: Moderate and severe OSA is associated with a decrease in Aβ42 plasma level. CPAP-therapy leads to increase this peptide in blood plasma. |
|---|---|
| ISSN: | 2158-0510 2158-0529 |